1. CorMedix Inc. (NASDAQ:CRMD)
CorMedix Inc. (NASDAQ: CRMD) takes first place for the strongest combination of commercial expansion and reported profitability in this selection. Second-quarter 2026 consolidated revenue and grant income reached $101.9 million, compared with $39.7 million a year earlier, an increase of approximately 157%. DefenCath contributed $66.1 million, while the acquired Melinta portfolio contributed $35.8 million. The headline growth therefore includes a meaningful acquisition contribution.
Profitability also advanced. Quarterly net income increased to $26 million from $19.8 million, while adjusted EBITDA rose to $58.7 million from $22.4 million. Cash and cash equivalents totaled $256.7 million at June 30.
The investment case now depends on sustaining DefenCath demand while integrating the broader portfolio. Acquisition-related expenses, customer purchasing patterns, and commercial execution could make future results uneven.
Ranking rationale
CorMedix earns the top position because its expansion is already producing meaningful earnings. Investors should still examine organic growth and current valuation before treating its operating momentum as a buying opportunity.
YOU MUST READ THIS: Top 6 Best AI Healthcare Stocks to Buy Today
Disclosure: No material interests to disclose. This article was originally published on BioTech HealthX.
